Canada (CA)

Serum organochlorines and non-Hodgkin lymphoma: A case-control study in Israeli Jews and Palestinians (2018) Klil-Drori AJ, Kleinstern G, Abu Seir R, Choshen-Cohen L, Abdeen Z, Hussein E, Aqel M, et al. Journal article Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study (2018) Feagan BG, Panes J, Ferrante M, Kaser A, D'Haens GR, Sandborn WJ, Louis E, et al. Journal article Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives (2018) De Boer NKH, Peyrin-Biroulet L, Jharap B, Sanderson JD, Meijer B, Atreya I, Barclay ML, et al. Journal article Upadacitinib improves steroid-free clinical and endoscopic endpoints in patients with Crohn's disease: Data from the CELEST study (2018) Panaccione R, Atreya R, Ferrante M, Dubinsky MC, Sands BE, Abreu MT, Cataldi F, et al. Conference contribution Real-time Interobserver Agreement in Bowel Ultrasonography for Diagnostic Assessment in Patients With Crohn's Disease: An International Multicenter Study (2018) Calabrese E, Kucharzik T, Maaser C, Maconi G, Strobel D, Wilson SR, Zorzi F, et al. Journal article rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology (2018) Kelemen LE, Earp M, Fridley BL, Chenevix-Trench G, Fasching P, Beckmann M, Ekici AB, et al. Journal article Effect of Seladelpar on Pruritus in Primary Biliary Cholangitis: 26-Week Analysis of an Ongoing International, randomized, Dose Ranging Phase 2 Study (2018) Kremer A, Bowlus CL, Neff GW, Aspinall R, Galambos MR, Goel A, Hirschfield G, et al. Conference contribution Final analysis of time to subsequent disease progression/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide Autogel/depot 120mg in the CLARINET open-label extension (2018) Pavel ME, Cwikla J, Wolin E, Phan A, Raderer M, Sedlackova E, Cadiot G, et al. Conference contribution ElevatION: NET-201 A Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients with Metastatic, Well-Differentiated NET of Pancreatic/GI/Thoracic Origin or Poorly-Differentiated GEP NEC Who Have Progressed on Prior Treatment (2018) Yao JC, Fazio N, Li D, Pavel ME, Strosberg J, Bergsland E, Ruszniewski P, et al. Conference contribution Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes with Everolimus: A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials (2018) Chan DL, Yao JC, Carnaghi C, Buzzoni R, Herbst F, Ridolfi A, Strosberg J, et al. Conference contribution